TO THE EDITOR
The conventional pharmacokinetic profiles of drugs are described mainly through the plotting of drug-plasma concentration against time. This is clearly appropriate for most of the orally administered drugs that undergo systemic absorption before distribution to the site of action. However some drugs, such as local anesthetics, antifungal agents, and topical corticosteroids, are designed to target the local tissue where they are applied and, as such, have limited systemic absorption. For these drugs, the pharmacokinetic measurements in the local tissue are of more interest than the systemic measurement. A number of in vitro and in vivo techniques are available for direct measurement of pharmacokinetic and clinically relevant information about drug concentration in the target tissue and skin. Animal skin and excised human skin are available to use in in vitro experiments such as those using Franz-type diffusion cells (Franz, 1976) . However, the data obtained from excised skin may not translate directly to the in vivo situation. There are a few in vivo techniques that enable acquisition of drug concentration information in the skin and a pharmacokinetic profile. These techniques include dermal microdialysis (DMD; Anderson et al., 1992; Hegemann et al., 1995; Benfeldt, 1999) , tape stripping or dermatopharmacokinetics (DPK; Pershing et al., 2003) , the skin blister fluid method (Nowak and Klimowicz, 1990) , magnetic resonance imaging (Jynge et al., 1990) , and biopsy followed by tissue homogenization (Roos and Brorson, 1990) .
Of these techniques, microdialysis and tape stripping are the most widely used for the pharmacokinetic assessment of skin because these methods are easier to perform, produce reliable results, and are less invasive.
In this study, which was approved by the United Kingdom's Central Office for Research Ethics Committees, we evaluated the DMD and tape-stripping (DPK) techniques in the pharmacokinetic assessment of topical drugs and compared the results with those of conventional systemic drug measurements in blood. The study was conducted according to the Declaration of Helsinki Principles. It was an openlabel study, with two visits and a 1-week washout period. DMD and blood sampling were performed in parallel on one occasion and DPK was performed on another occasion. The study involved 12 healthy subjects, and participants gave their written informed consent. On the microdialysis study day, a CMA 60 microdialysis catheter was used together with a CMA 106 microdialysis pump supplied by CMA Microdialysis, Solna, Sweden. The adhesive tape used on the DPK study day was TESA 4204 PV5, supplied by TESA, Milton Keyness, UK. EMLA cream (AstraZeneca, Bristol, UK) containing 2.5% lidocaine and 2.5% prilocaine was used as a study drug. In the DMD experiment, the probe (3 cm long) was inserted under the treatment area (subcutaneous tissue) and the sampling was carried out every 20 minutes until 4 hours after the dose. The treatment was 1 g EMLA cream applied to a 10-cm 2 circular area of the skin.
A 20-gauge cannula was cannulated on the contralateral arm for the venous sampling. Venous samples were collected at 0, 20, and 40 minutes and 1, 1.5, 2, 2.5, 3, 3.5, and 4 hours after the dose. The residual drug was removed from the treated area 1 hour after treatment application. On another occasion, the tape stripping was carried out on the skin surface. Tape stripping was performed at 0, 15, 30, and 45 min and 1 hour after the dose for the uptake phase (sites 1, 2, 3, 4, and 5) and 1.5, 2, 3, and 4 hours after the dose for the elimination phase (sites 6, 7, 8, and 9). The treatments were 1 g EMLA cream applied to 10 demarcated rectangular areas of the skin (6 cm 2 ). Before collection of stratum corneum from the treated skin site, the residual product was removed from the skin surface using a metal spatula and three dry cotton-wool tips used independently. Site 1 served as a control (0 hour sampling). The residual product was removed at 15, 30, and 45 min from sites 2, 3, and 4. For sites 5-9, the residual product was removed at 1 hour. After product removal from the skin, the first adhesive tape was applied and briskly rubbed with bluntended forceps to collect the stratum corneum. The tape was removed using the forceps. As a precaution, the first adhesive tape was discarded to avoid potential contamination from any residual product not removed with the dry cotton wool (Weigmann et al., 1999) . The remaining nine adhesive tapes were applied sequentially using the procedure described above and kept in a polypropylene tube until further analysis. The lidocaine concentration from plasma and DMD samples was 
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Abbreviations: DMD, dermal microdialysis; DPK, dermatopharmacokinetic analyzed using the validated liquid chromatography-mass spectrometry/mass spectrometry method (Chik et al., 2006) , and the lidocaine content in the tape samples was analyzed using capillary electrophoresis with UV detection (Chik et al., 2007) . Table 1 summarizes the pharmacokinetic parameters derived for lidocaine, and Figure 1 shows the lidocaine concentration-versus-time plot for all the three methods studied. There was a higher area under the curve and C max (maximum plasma concentration) with DPK as compared with DMD and plasma. The median time to the highest plasma lidocaine concentration, t max , was significantly shorter in the stratum corneum as compared with plasma, with values of 1.00 versus 3.25 hours (Po0.001). The higher lidocaine profile yielded by the DPK and DMD methods is advantageous for pharmacokinetic measurement when compared with the low lidocaine profiles obtained from systemic measurement. The results showed that lidocaine was rapidly detected in the stratum corneum soon after treatment application. At 1 hour after application of EMLA, its levels in the stratum corneum were higher than those in the subcutaneous layer of the skin or in blood. The decrease in the amount of lidocaine after 1 hour in the DPK samples can be explained by the increased of lidocaine concentration in the dialysate. This remained elevated even at the 4-hour sampling time. In a comparison of the DPK and DMD methods, good reproducibility and less variability were shown by the DPK method. The greater variability in the DMD data than with plasma and DPK may be a reflection of the depth of the probe implantation, as the same subjects were used for all three techniques. Moreover, the validation of within-and between-probe recovery showed a low variability in the three probes studied. Therefore, between-and within-probe variability was minimal and did not contribute significantly to the variability observed. However, more research and data regarding the reliability of DMD and DPK are necessary to determine the ideal methods for pharmacokinetic assessment of topical drugs. 
